368 related articles for article (PubMed ID: 31337271)
1. Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels.
Brown BM; Shim H; Christophersen P; Wulff H
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():219-240. PubMed ID: 31337271
[TBL] [Abstract][Full Text] [Related]
2. Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.
Wulff H; Köhler R
J Cardiovasc Pharmacol; 2013 Feb; 61(2):102-12. PubMed ID: 23107876
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1).
Christophersen P; Wulff H
Channels (Austin); 2015; 9(6):336-43. PubMed ID: 26217968
[TBL] [Abstract][Full Text] [Related]
4. Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3.
Oliván-Viguera A; Valero MS; Murillo MD; Wulff H; García-Otín AL; Arbonés-Mainar JM; Köhler R
PLoS One; 2013; 8(3):e58614. PubMed ID: 23516517
[TBL] [Abstract][Full Text] [Related]
5. Channelopathy of small- and intermediate-conductance Ca
Nam YW; Downey M; Rahman MA; Cui M; Zhang M
Acta Pharmacol Sin; 2023 Feb; 44(2):259-267. PubMed ID: 35715699
[TBL] [Abstract][Full Text] [Related]
6. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.
Wulff H; Kolski-Andreaco A; Sankaranarayanan A; Sabatier JM; Shakkottai V
Curr Med Chem; 2007; 14(13):1437-57. PubMed ID: 17584055
[TBL] [Abstract][Full Text] [Related]
7. Role of S3 and S4 transmembrane domain charged amino acids in channel biogenesis and gating of KCa2.3 and KCa3.1.
Gao Y; Chotoo CK; Balut CM; Sun F; Bailey MA; Devor DC
J Biol Chem; 2008 Apr; 283(14):9049-59. PubMed ID: 18227067
[TBL] [Abstract][Full Text] [Related]
8. Endothelial K
Li JJ; Zhao XY; Wang Y; Xu R; Di XH; Zhang Y; Yang H; Han MZ; Bai RY; Xie L; Pang ZD; Zhang X; Zhang J; Du XJ; Deng XL; Zhang Y; Xie W
Arterioscler Thromb Vasc Biol; 2023 May; 43(5):726-738. PubMed ID: 36951065
[TBL] [Abstract][Full Text] [Related]
9. A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.
Oliván-Viguera A; Valero MS; Coleman N; Brown BM; Laría C; Murillo MD; Gálvez JA; Díaz-de-Villegas MD; Wulff H; Badorrey R; Köhler R
Mol Pharmacol; 2015 Feb; 87(2):338-48. PubMed ID: 25468883
[TBL] [Abstract][Full Text] [Related]
10. Laminar shear stress upregulates endothelial Ca²⁺-activated K⁺ channels KCa2.3 and KCa3.1 via a Ca²⁺/calmodulin-dependent protein kinase kinase/Akt/p300 cascade.
Takai J; Santu A; Zheng H; Koh SD; Ohta M; Filimban LM; Lemaître V; Teraoka R; Jo H; Miura H
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H484-93. PubMed ID: 23792675
[TBL] [Abstract][Full Text] [Related]
11. New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1.
Coleman N; Brown BM; Oliván-Viguera A; Singh V; Olmstead MM; Valero MS; Köhler R; Wulff H
Mol Pharmacol; 2014 Sep; 86(3):342-57. PubMed ID: 24958817
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary hypertension in wild type mice and animals with genetic deficit in KCa2.3 and KCa3.1 channels.
Wandall-Frostholm C; Skaarup LM; Sadda V; Nielsen G; Hedegaard ER; Mogensen S; Köhler R; Simonsen U
PLoS One; 2014; 9(5):e97687. PubMed ID: 24858807
[TBL] [Abstract][Full Text] [Related]
13. Channelopathy-causing mutations in the S
Orfali R; Nam YW; Nguyen HM; Rahman MA; Yang G; Cui M; Wulff H; Zhang M
Cell Calcium; 2022 Mar; 102():102538. PubMed ID: 35030515
[TBL] [Abstract][Full Text] [Related]
14. Endothelial Small- and Intermediate-Conductance K Channels and Endothelium-Dependent Hyperpolarization as Drug Targets in Cardiovascular Disease.
Köhler R; Oliván-Viguera A; Wulff H
Adv Pharmacol; 2016; 77():65-104. PubMed ID: 27451095
[TBL] [Abstract][Full Text] [Related]
15. Trafficking of intermediate (KCa3.1) and small (KCa2.x) conductance, Ca(2+)-activated K(+) channels: a novel target for medicinal chemistry efforts?
Balut CM; Hamilton KL; Devor DC
ChemMedChem; 2012 Oct; 7(10):1741-55. PubMed ID: 22887933
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of vascular calcium-gated chloride currents by blockers of KCa1.1, but not by modulators of KCa2.1 or KCa2.3 channels.
Sones WR; Leblanc N; Greenwood IA
Br J Pharmacol; 2009 Sep; 158(2):521-31. PubMed ID: 19645713
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end products impair K(Ca)3.1- and K(Ca)2.3-mediated vasodilatation via oxidative stress in rat mesenteric arteries.
Zhao LM; Wang Y; Ma XZ; Wang NP; Deng XL
Pflugers Arch; 2014 Feb; 466(2):307-17. PubMed ID: 23873353
[TBL] [Abstract][Full Text] [Related]
18. Ca
Orfali R; Albanyan N
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677942
[TBL] [Abstract][Full Text] [Related]
19. Voltage dependence of the Ca(2+)-activated K(+) channel K(Ca)3.1 in human erythroleukemia cells.
Stoneking CJ; Shivakumar O; Thomas DN; Colledge WH; Mason MJ
Am J Physiol Cell Physiol; 2013 May; 304(9):C858-72. PubMed ID: 23407879
[TBL] [Abstract][Full Text] [Related]
20. The influence of DOCA-salt hypertension and chronic administration of the FAAH inhibitor URB597 on K
Kloza M; Baranowska-Kuczko M; Malinowska B; Karpińska O; Harasim-Symbor E; Kasacka I; Kozłowska H
Vascul Pharmacol; 2017 Dec; 99():65-73. PubMed ID: 29038048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]